Cargando…

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases. Little is known about how EZH2 affects patients’ response to therapy. In this context, the aim of this study was to retrospectively analyze the frequency of mutations in EZH2 at diagnosis in tissue and ctDNA in patients with FL and to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martínez-Laperche, C., Sanz-Villanueva, L., Díaz Crespo, F. J., Muñiz, P., Martín Rojas, R., Carbonell, D., Chicano, M., Suárez-González, J., Menárguez, J., Kwon, M., Diez Martín, J. L., Buño, I., Bastos Oreiro, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476261/ https://www.ncbi.nlm.nih.gov/pubmed/36104682 http://dx.doi.org/10.1186/s12885-022-10070-z

Ejemplares similares

Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
por: Martínez-Laperche, C., et al.
Publicado: (2022)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin’s lymphoma
por: Bastos-Oreiro, Mariana, et al.
Publicado: (2021)

P1423: CIRCULATING CELL-FREE DNA KINETICS MEASURED BY DIGITAL PCR IN LYMPHOMA PATIENTS UNDERGOING CD19-CAR-T THERAPY
por: López-Esteban, M., et al.
Publicado: (2022)

P1427: MONITORING CAR-T CELL IN B-CELL LYMPHOMA PATIENTS THROUGH SINGLE CHAIN VARIABLE FRAGMENT BY DIGITAL PCR
por: De La Iglesia San Sebastián, I., et al.
Publicado: (2022)

Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms
por: Carbonell, Diego, et al.
Publicado: (2019)

Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations
por: Chicano, María, et al.
Publicado: (2021)

Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide
por: Muñiz, Paula, et al.
Publicado: (2021)

Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide
por: Solán, Laura, et al.
Publicado: (2021)

Clinical utility of targeted next‐generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition
por: Andrés‐Zayas, Cristina, et al.
Publicado: (2021)

Short Tandem Repeats (STRs) as Biomarkers for the Quantitative Follow-Up of Chimerism after Stem Cell Transplantation: Methodological Considerations and Clinical Application
por: Navarro-Bailón, Almudena, et al.
Publicado: (2020)

Novel Candidate loci and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome Sequencing
por: Andrés-Zayas, Cristina, et al.
Publicado: (2023)

FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia
por: Carbonell, Diego, et al.
Publicado: (2022)

ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide
por: Solán, Laura, et al.
Publicado: (2019)

Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation
por: Muñiz, Paula, et al.
Publicado: (2022)

Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma
por: Bastos‐Oreiro, Mariana, et al.
Publicado: (2021)

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel
por: Martín‐Rojas, Reyes Maria, et al.
Publicado: (2022)

EZH2 alterations in follicular lymphoma: biological and clinical correlations
por: Huet, S, et al.
Publicado: (2017)

Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms
por: Vallejo, Miren, et al.
Publicado: (2022)

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
por: Merryman, Reid W., et al.
Publicado: (2023)

EZH2 in Bladder Cancer, a Promising Therapeutic Target
por: Martínez-Fernández, Mónica, et al.
Publicado: (2015)

Blockchain and medicine: From digital promise to frontline practice
por: Abadeh, Armin
Publicado: (2022)

Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin
por: Morin, Ryan D., et al.
Publicado: (2010)

Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma
por: Nagy, Ákos, et al.
Publicado: (2020)

Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS
por: Ciarapica, Roberta, et al.
Publicado: (2014)

lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma
por: Wozniak, Michal, et al.
Publicado: (2023)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)
por: Hamadani, M., et al.
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

The role of EZH2 in tumour progression
por: Chang, C-J, et al.
Publicado: (2012)

The role of EZH2 in overall survival of colorectal cancer: a meta-analysis
por: Vilorio-Marqués, Laura, et al.
Publicado: (2017)

The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection
por: Chen, Xiangyu, et al.
Publicado: (2019)

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

Health Workers on the Political Frontlines
por: Lasco, Gideon, et al.
Publicado: (2022)

Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection
por: Miles, Brodie, et al.
Publicado: (2015)

Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
por: Jiménez-Ubieto, Ana, et al.
Publicado: (2023)

Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas
por: Schümann, Franziska Lea, et al.
Publicado: (2021)

The role of EZH1 and EZH2 in development and cancer
por: Lee, Soo Hyun, et al.
Publicado: (2022)

Mucins: the frontline defence of the lung
por: Ridley, Caroline, et al.
Publicado: (2018)

Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
por: Jiménez-Ubieto, Ana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nmf1luh2r2uaciaqe3v9cgo5i5